Neuroblastoma Drugs Market size was valued at USD 254.78 billion in 2024 and is set to exceed USD 498.58 billion by 2037, expanding at over 5.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of neuroblastoma drugs is estimated at USD 276.84 billion.
The growth of the market can be attributed to the increasing childhood cancer and rising incidence of neuroblastoma. As per the estimations, more than 700 children are diagnosed with neuroblastoma each year in the United States as of 2023. The growing awareness of people regarding the diagnosis and treatment of cancer is estimated to drive market growth. The increasing occurrence of gender-specific and age-specific incident cases is expected to boost industry growth in the coming years. The rising occurrence of neuroblastoma from gene mutations in families is also estimated to hike industry growth.
The increasing research and development in neuroblastoma treatment owing to the rising expenditure on cancer treatment is estimated to drive market growth. The rising birth rate across the world and increasing clinical trials to improve treatment procedures are estimated to propel the growth of the market. The U.S. birth rate from 2020 to 2021 was estimated to increase by 1% after a decrease of 3% from 2019 to 2020. The market growth is attributed to the rising availability of reimbursement in the healthcare sector for the treatment of neuroblastoma. The government initiatives to increase healthcare expenditure across the globe to reduce the spread of diseases are also estimated to rise the demand for the market during the forecast period.
Growth Drivers
Rising Healthcare Spending across the World Owing to the Growing Diseases – - The world's healthcare spending is expected to rise in the next years as a result of the aging population, rising disease incidence, and increased demand for medical services, among other factors. The rising healthcare cost, service, and pharmaceutical drug prices are estimated to hike the market growth.
Healthcare spending in the U.S. increased by over 2.5% reaching more than USD 4 trillion which was USD 13000 per person as of 2021.
Growing Prevalence of Cancers Cases Among Children and Adults – The increasing occurrence of new cancer cases across the U.S. is estimated to increase to 30 million every year by the end of 2040.
Increasing Practice of Chemotherapy as First-of-Line Treatment – The increasing number of patients undergoing chemotherapy as first-line of treatment across the world per annum is estimated to rise by over 50% from 10 million to 14 million from 2019 to 2040.
High Number of People Taking Early Diagnosis Tests to Prevent Complications – Across the U.S. more than 25% of cases are diagnosed at early stages as of 2022 estimations.
Growing Cancer Institutes Conducting Research and Development Programs – The research of new drug developments in cancer led to 12 new drug approvals by the U.S. Food and Drug Administration for oncology as of 2023.
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.3% |
|
Base Year Market Size (2024) |
USD 254.78 billion |
|
Forecast Year Market Size (2037) |
USD 498.58 billion |
|
Regional Scope |
|
Mechanism Type (Antibiotics, Microtubule Inhibitors, Alkylating Agents)
The market is segmented and analyzed for demand and supply by mechanism type into antibiotics, microtubule inhibitors, alkylating agents, and others. Out of these types, the antibiotics segment is estimated to gain the largest market share of about 42% in the year 2037. The growth of the segment can be attributed to the increasing use of antibiotics for neuroblastoma. The rising applications of antibiotics such as tigecycline which is an expanded spectrum antibiotic in cancer therapy are also estimated to drive the market segment growth during the forecast period. The growing population who uses antibiotics against neuroblastoma to produce anti-proliferative effects on the cells is also estimated to hike the market segment growth. The use of antibiotics suppresses the growth of tumor cell colonies thereby reducing the further spread of cancer to other parts which is anticipated to have a positive impact on the market segment growth. Every year more than 250 million antibiotic prescriptions are given in the U.S. as of 2019.
Treatment Type (Chemotherapy, Bone Marrow Transplantation, Retinoid Therapy, Immunotherapy, Surgery)
The neuroblastoma drugs market is also segmented and analyzed for demand and supply by treatment type into chemotherapy, bone marrow transplantation, retinoid therapy, immunotherapy, and surgery. Amongst these three segments, the chemotherapy segment is expected to garner a significant share of around 32% in the year 2037. The chemotherapy segment is anticipated to witness significant growth on the back of the rising usage of chemotherapy drugs such as doxorubicin and carboplatin in order to destroy cancer cells. Moreover, chemotherapy is used as a primary treatment for cancer as it helps in the shrinkage of tumor cells which makes other treatments such as surgery or radiation possible. Besides drug therapy, chemotherapy is the next best treatment method to improve cancer conditions and is thus estimated to hike the segment growth. The number of chemotherapy centers in clinics and hospitals owing to the improvement in the infrastructure of public and private sectors is anticipated to rise the demand for market segment growth during the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Mechanism Type |
|
|
By Treatment Type |
|
|
By Diagnosis Type |
|
|
By End User |
|
North American Market Forecast
North America industry is estimated to hold largest revenue share of 36% by 2037. This growth is attributed to the rise in technologically enhanced drugs along with the increase in incidences of neuroblastoma. As of 2020 estimations more than USD 190 billion was spent on healthcare of cancer in 2015 and was projected to increase to over USD 200 billion in 2020 in the U.S. Further, growing investments in the healthcare sector and approval of orphan drugs for the treatment of neuroblastoma are boosting the market growth. The rising number of people undergoing chemotherapy and drug treatments to reduce further complications of the disease is anticipated to propel the market growth. The market growth is also attributed to the growing patient population with immune suppression with age and other disease conditions. The increasing change in food habits and high consumption of plastic containers and silver foil containers for food delivery is also estimated to rise the market growth. The growing population with less physical activity and high exposure to radiation that initiate mutations in the gene are the reason for the market growth. More people suffering from immune suppressive disorders such as diabetes are more prone to diseases causing major threats to the incidence of cancer tumors and is estimated to drive market growth.
Europe Market Forecast
The European neuroblastoma drugs market is estimated to be the second largest, registering a share of about 27% by the end of 2037. The growth of the market can be attributed majorly to the increasing prevalence of cancer in children along with the increase in spending on cancer treatment. Additionally, the first drug approved for the cure of neuroblastoma that is anti-GD2 is witnessing huge demand owing to its site-specific action and no cytotoxic effects on the body. Further, the increasing newborn population in the region along with the development of advanced novel therapies for the treatment of neuroblastoma is fostering the market growth. Furthermore, increased awareness of the diagnosis and treatment of neuroblastoma has permitted the focus on new tumor targets for the advancement of cell-mediated immunotherapy medicines for cancer. Hence, these factors are estimated to fuel the growth of the market over the forecast period. The market in Europe is estimated to witness significant growth on the account of the rising number of child healthcare centers for the treatment of cancer along with the increasing awareness related to good health.
APAC Market Statistics
Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the increasing aging population and poor healthcare facilities. The Asia Pacific region is anticipated to be the fastest growing market on the back of the presence of emerging nations leading to a surge in children’s cancer base. The occurrence of COVID-19 leading to a decrease in the immune system’s capacity to fight against any disease is estimated to drive market growth. The number of cases of neuroblastoma in children and the elderly with a lack of awareness of the disease is also anticipated to hike the growth of the market. The increasing research institutes of cancer that conduct clinical trials for the discovery of new drugs to prevent the spread of the disease is expected to rise the market growth. The increasing number of healthcare centers with chemotherapy, drug therapy, and reimbursement policies to enhance the living standards of people in the region is also estimated to fuel the market growth in the coming years.
Teva Pharmaceutical Industries Ltd. in Association with Global HOPE (Hematology Oncology Pediatric Excellence) donated over 566,000 doses of medicine, and helped with the training of over 5,600 healthcare professionals across Africa by providing required care, health services, and medical resources.
Eli Lilly and Company started research on genomic testing in cancer in order to find weaknesses in tumor makeup and to design more targeted treatment. Further, Lilly Oncology is working to spread the knowledge about genomic testing in cancer diagnosis and treatment.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?